Lei Lei

Publication Activity (10 Years)

Years Active: 2019-2023
Publications (10 Years): 6

Top Topics

Metastatic Breast Cancer

Epithelial Mesenchymal Transition

Top Venues

NPJ breast cancer

OncoTargets and therapy

Journal of breast cancer

This page only lists publications with an associated author ORCID identifier.

Publications

Zi-Yan Yang, Jianguo Feng, Ji Jing, Yuan Huang, Wei-Wu Ye, Lei Lei, Xiao-Jia Wang, Wen-Ming Cao
Resistance to anti-HER2 therapy associated with the TSC2 nonsynonymous variant c.4349 C > G (p.Pro1450Arg) is reversed by CDK4/6 inhibitor in HER2-positive breast cancer. NPJ breast cancer 9 (1) (2023)
Zi-Yan Yang, Jianguo Feng, Ji Jing, Yuan Huang, Wei-Wu Ye, Lei Lei, Xiao-Jia Wang, Wen-Ming Cao
Resistance to anti-HER2 therapy associated with the TSC2 nonsynonymous variant c.4349 C > G (p.Pro1450Arg) is reversed by CDK4/6 inhibitor in HER2-positive breast cancer. NPJ breast cancer 9 (1) (2023)
Jia-Ni Pan, Lei Lei, Wei-Wu Ye, Xiao-Jia Wang, Wen-Ming Cao
BRCA1 Reversion Mutation Confers Resistance to Olaparib and Camrelizumab in a Patient with Breast Cancer Liver Metastasis. Journal of breast cancer 24 (5) (2021)
Zi-Yan Yang, Liu Yang, Chun-Wei Xu, Xiao-Jia Wang, Lei Lei
An insertion mutation of ERBB2 enhances breast cancer cell growth and confers resistance to lapatinib through AKT signaling pathway. Biology open 9 (1) (2020)
Zi-Yan Yang, Nani Li, Xiaolin Li, Lei Lei, Xiaojia Wang
The Prognostic Impact of Hormonal Receptor and HER-2 Expression Discordance in Metastatic Breast Cancer Patients. OncoTargets and therapy 13 (2020)
Lei Lei, Wen-Xian Wang, You-Cai Zhu, Jin-Luan Li, Yong Fang, Hong Wang, Wu Zhuang, Yin-Bin Zhang, Li-Ping Wang, Mei-Yu Fang, Chun-Wei Xu, Xiao-Jia Wang, Tang-Feng Lv, Tang-Feng Lv
Real-world efficacy and potential mechanism of resistance of icotinib in Asian advanced non-small cell lung cancer with EGFR uncommon mutations: A multi-center study. Cancer medicine 9 (1) (2019)